Drug-coated Balloon Angioplasty For Ischemic Stroke Within 30 Days Caused By Intracranial Arterial Stenosis ( BASIS-2 )
NCT07931885, Not applicable, Not yet recruiting, Beijing Tiantan Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Drug-coated Balloon Angioplasty For Ischemic Stroke Within 30 Days Caused By Intracranial Arterial Stenosis ( BASIS-2 ) | ClinicalTrials.gov |
| NCT number | NCT07931885 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 360 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Beijing Tiantan Hospital | ClinicalTrials.gov |
| Conditions | Intracranial Atherosclerotic Stenosis | ClinicalTrials.gov |
| Interventions | Drug therapy administration, Intracranial artery balloon dilatation combined with intensive medical treatment | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Any new stroke (ischemic/hemorrhagic stroke) and all-cause death within 30 days after enrollment or ischemic stroke in the target blood supply area within 31 days to 12 months after enrollment | Within 30 days after enrollment;Within 12 months after enrollment | Any new stroke (ischemic/hemorrhagic stroke) and all-cause death within 30 days after enrollment or ischemic stroke in the target blood supply area within 31 days to 12 months after enrollment | ClinicalTrials.gov |
| Secondary | Any stroke (ischemic/hemorrhagic stroke) and all-cause death within 30 days after enrollment | Within 30 days after enrollment | Any stroke (ischemic/hemorrhagic stroke) and all-cause death within 30 days after enrollment. | ClinicalTrials.gov |
| Secondary | Any stroke (hemorrhagic/ischemic stroke) or death in the target vessel supply area within 90 days of enrollment | Within 90 days of enrollment | Any stroke (hemorrhagic/ischemic stroke) or death in the target vessel supply area within 90 days of enrollment. | ClinicalTrials.gov |
| Secondary | Any stroke (hemorrhagic/ischemic stroke) outside the target blood supply area within 90 days of enrollment | Within 90 days of enrollment | Any stroke (hemorrhagic/ischemic stroke) outside the target blood supply area within 90 days of enrollment. | ClinicalTrials.gov |
| Secondary | Assessment of neurological function improvement within 90 days of enrollment (mRS score) | Within 90 days of enrollment | The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability,5 severe disability, and 6 death. | ClinicalTrials.gov |
| Secondary | Assessment of neurological function improvement within 180 days of enrollment (mRS score) | Within 180 days of enrollment | The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability,5 severe disability, and 6 death. | ClinicalTrials.gov |
| Secondary | Any stroke (hemorrhagic/ischemic stroke) or death in the target vascular supply area within 12 months of enrollment | Within 12 months of enrollment | Any stroke (hemorrhagic/ischemic stroke) or death in the target vascular supply area within 12 months of enrollment. | ClinicalTrials.gov |
| Secondary | Target vessel revascularization within 12 months of enrollment | Within 12 months of enrollment | Target vessel revascularization within 12 months of enrollment. | ClinicalTrials.gov |
| Secondary | Any stroke (hemorrhagic/ischemic stroke) outside the target blood supply area within 12 months of enrollment | Within 12 months of enrollment | Any stroke (hemorrhagic/ischemic stroke) outside the target blood supply area within 12 months of enrollment. | ClinicalTrials.gov |
| Secondary | Assessment of neurological function improvement within 12 months of enrollment (mRS score) | Within 12 months of enrollment | The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability,5 severe disability, and 6 death. | ClinicalTrials.gov |
| Secondary | The incidence of vascular restenosis within 12 months of enrollment | Within 12 months of enrollment | The incidence of vascular restenosis within 12 months of enrollment. | ClinicalTrials.gov |
| Secondary | Composite events such as stroke, myocardial infarction, and vascular death within 12 months of enrollment | Within 12 months of enrollment | Composite events such as stroke, myocardial infarction, and vascular death within 12 months of enrollment. | ClinicalTrials.gov |
| Secondary | Quality of life assessment within 12 months of enrollment (EQ-5D scale) | Within 12 months of enrollment | The change in functional health status and quality of life measured by EuroQol five dimensions questionnaire (EQ-5D) within 12 months of enrollment. | ClinicalTrials.gov |
| Secondary | Any stroke (hemorrhagic/ischemic stroke) or death in the target vascular supply area within 24 months of enrollment | Within 24 months of enrollment | Any stroke (hemorrhagic/ischemic stroke) or death in the target vascular supply area within 24 months of enrollment. | ClinicalTrials.gov |
| Secondary | Any stroke (hemorrhagic/ischemic stroke) outside the target blood supply area within 24 months of enrollment | Within 24 months of enrollment | Any stroke (hemorrhagic/ischemic stroke) outside the target blood supply area within 24 months of enrollment. | ClinicalTrials.gov |
| Secondary | Assessment of neurological function improvement within 24 months of enrollment (mRS score) | Within 24 months of enrollment | The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability,5 severe disability, and 6 death. | ClinicalTrials.gov |
| Secondary | Composite events such as stroke, myocardial infarction, and vascular death within 24 months of enrollment | Within 24 months of enrollment | Composite events such as stroke, myocardial infarction, and vascular death within 24 months of enrollment. | ClinicalTrials.gov |
| Secondary | Any stroke (hemorrhagic/ischemic stroke) or death in the target vascular supply area within 36 months of enrollment | Within 36 months of enrollment | Any stroke (hemorrhagic/ischemic stroke) or death in the target vascular supply area within 36 months of enrollment. | ClinicalTrials.gov |
| Secondary | Any stroke (hemorrhagic/ischemic stroke) outside the target vascular supply area within 36 months of enrollment | Within 36 months of enrollment | Any stroke (hemorrhagic/ischemic stroke) outside the target vascular supply area within 36 months of enrollment. | ClinicalTrials.gov |
| Secondary | Assessment of neurological function improvement within 36 months of enrollment (mRS score) | Within 36 months of enrollment | The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability,5 severe disability, and 6 death. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)